Dr. Reddy’s Laboratories has received a Pre-Approval Inspection (PAI) letter from the US Food and Drug Administration (USFDA) for its biologics facility located in Hyderabad, India. This letter indicates that the USFDA has completed its inspection of the facility and has found it to be compliant with the required standards.<\/p>\n
The USFDA conducts pre-approval inspections to ensure that manufacturing facilities meet the necessary regulatory requirements before approving a new drug application. The inspection is a critical step in the approval process, and receiving a PAI letter is a significant milestone for Dr. Reddy’s Laboratories.<\/p>\n
The Hyderabad biologics facility is a state-of-the-art manufacturing site that produces a range of biological products, including monoclonal antibodies and other biologic drugs. The facility has been designed to meet the highest international standards of quality and safety, and the USFDA’s pre-approval inspection is a testament to the facility’s compliance with these standards.<\/p>\n
The receipt of the PAI letter is a positive development for Dr. Reddy’s Laboratories, as it brings the company one step closer to receiving approval for its biologic products in the US market. The company has been expanding its presence in the biologics market in recent years, and this development is expected to further strengthen its position in this segment.<\/p>\n
The USFDA’s inspection process is rigorous and thorough, and the fact that Dr. Reddy’s Laboratories has received a PAI letter suggests that the facility has met the required standards. The company will now await the final approval from the USFDA, which is expected to be granted in the coming months.<\/p>\n
The approval of Dr. Reddy’s biologics facility by the USFDA is significant not only for the company but also for the Indian pharmaceutical industry as a whole. It demonstrates the capability of Indian companies to meet international standards of quality and safety, and it is expected to boost the confidence of global regulatory agencies in the Indian pharmaceutical industry.<\/p>\n
In conclusion, the receipt of the PAI letter by Dr. Reddy’s Laboratories is a significant development that brings the company closer to receiving approval for its biologic products in the US market. The company’s biologics facility in Hyderabad has been found to be compliant with the required standards, and the final approval from the USFDA is expected to be granted in the coming months. This development is expected to further strengthen Dr. Reddy’s position in the biologics market and boost the confidence of global regulatory agencies in the Indian pharmaceutical industry.<\/p>\n","protected":false},"excerpt":{"rendered":"
Dr. Reddy’s Laboratories has received a Pre-Approval Inspection (PAI) letter from the US Food and Drug Administration (USFDA) for its biologics facility located in Hyderabad, India. This letter indicates that the USFDA has completed its inspection of the facility and has found it to be compliant with the required standards. The USFDA conducts pre-approval inspections […]<\/p>\n","protected":false},"author":1,"featured_media":88041,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[15],"tags":[],"class_list":["post-89794","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dr-reddys"],"jetpack_featured_media_url":"https:\/\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89737,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/02\/usfda-deals-a-blow-to-dr-reddys-biosimilar-denosumab-avt03-following-an-inspection-of-the-manufacturing-facility\/","url_meta":{"origin":89794,"position":0},"title":"USFDA deals a blow to Dr Reddy’s biosimilar denosumab AVT03 following an inspection of the manufacturing facility.","author":"Team Small News","date":"January 2, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories has faced a setback in its efforts to bring its denosumab biosimilar, AVT03, to the US market. The US Food and Drug Administration (USFDA) has issued a warning letter to the company after conducting an inspection of its manufacturing facility. The inspection revealed several issues with the\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89847,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/24\/us-fda-concludes-inspection-at-zydus-ankleshwar-facility-with-three-noted-observations\/","url_meta":{"origin":89794,"position":1},"title":"US FDA Concludes Inspection at Zydus’ Ankleshwar Facility with Three Noted Observations.","author":"Team Small News","date":"January 24, 2026","format":false,"excerpt":"The US Food and Drug Administration (USFDA) has completed an inspection at Zydus Cadila's manufacturing facility in Ankleshwar, Gujarat, with three observations. The inspection was conducted from February 13 to February 17, 2023. Although the company has not provided detailed information about the observations, it has stated that they are\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89802,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/15\/dr-reddys-introduces-generic-version-of-antihistamine-eye-drops-to-the-us-market\/","url_meta":{"origin":89794,"position":2},"title":"Dr Reddy’s introduces generic version of antihistamine eye drops to the US market","author":"Team Small News","date":"January 15, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories has launched an over-the-counter (OTC) eye drop solution, Olopatadine Hydrochloride Ophthalmic Solution, in the US market. The solution is a generic equivalent of Extra Strength Pataday Once-Daily Relief, which is used to provide temporary relief from itchy eyes caused by pollen, ragweed, grass, animal hair, and dander.\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89727,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/31\/gurupyar-reddy-production-complex-injections-head-at-dr-reddys-laboratories\/","url_meta":{"origin":89794,"position":3},"title":"Gurupyar Reddy, Production Complex Injections Head at Dr Reddy’s Laboratories","author":"Team Small News","date":"December 31, 2025","format":false,"excerpt":"The Vizag Pharma Summit 2025 is scheduled to take place on December 17th, 2025, at the Fairfield by Marriott in Vizag. The event will feature a speaker, Mr. Gurupyar Reddy, who is the Head of Production Complex Injections at Dr. Reddy's Laboratories. Mr. Reddy will be discussing the topic of\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89836,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/22\/dr-reddys-relies-on-biosimilars-and-weight-loss-medication-launches-to-compensate-for-declining-us-dominance-of-revlimid\/","url_meta":{"origin":89794,"position":4},"title":"Dr Reddy’s relies on biosimilars and weight-loss medication launches to compensate for declining US dominance of Revlimid.","author":"Team Small News","date":"January 22, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories, a leading Indian pharmaceutical company, is shifting its focus towards biosimilars and a new weight-loss drug to drive growth as its exclusivity for the generic version of Revlimid in the US market is set to expire. Revlimid, a blood cancer treatment, has been a significant contributor to\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89705,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/25\/former-dr-reddys-facility-in-shreveport-gets-new-signage-frymaster\/","url_meta":{"origin":89794,"position":5},"title":"Former Dr. Reddy’s facility in Shreveport gets new signage: Frymaster.","author":"Team Small News","date":"December 25, 2025","format":false,"excerpt":"A new sign has been erected at the former Dr. Reddy's plant in Shreveport, indicating that Frymaster, a commercial fryer manufacturer, will be occupying the space. This development marks a significant turning point for the facility, which was previously home to Dr. Reddy's, a pharmaceutical company. The sign's installation suggests\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89794"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89794\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media\/88041"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89794"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}